Ucb

UCB, a pharmaceutical preparation manufacturer headquartered in Belgium, reported total carbon emissions of approximately 871.57 million kg CO2e in 2025. This includes about 22.19 million kg CO2e from Scope 1, 15,000 kg CO2e from Scope 2 (market-based), and 849.79 million kg CO2e from Scope 3 emissions.

UCB has set several climate commitments. The company aims to achieve net-zero greenhouse gas emissions across its value chain by 2045.

Near-term targets validated by the Science Based Targets initiative (SBTi) include:

• Reducing absolute Scope 1 and 2 GHG emissions by 73% by 2030 from a 2019 base year.
• Reducing absolute Scope 3 GHG emissions (from fuel- and energy-related activities, upstream transportation and distribution, waste generated in operations, business travel, employee commuting, upstream leased assets, and end-of-life treatment of sold products) by 48% by 2030 from a 2019 base year.
• Ensuring that 80% of its suppliers by emissions covering purchased goods and services will have science-based targets by 2028.

Long-term targets validated by SBTi include:

• Reducing absolute Scope 1 and 2 GHG emissions by 90% by 2045 from a 2019 base year.
• Reducing absolute Scope 3 GHG emissions from purchased goods and services, fuel- and energy-related activities, upstream transportation and distribution, waste generated in operations, business travel, employee commuting, upstream leased assets, and end-of-life treatment of sold products by 90% by 2045 from a 2019 base year.

Previously, UCB had committed to reducing GHG emissions by 35% by 2030 and by 70% by 2050 for Scope 1 and Scope 2, from a 2016 base year. They also committed to becoming carbon neutral for directly controlled operations by 2030, based on a 2015 baseline. Additionally, UCB had an SBTi commitment to reduce absolute Scope 1, 2, and 3 GHG emissions by 38% by 2030 from a 2015 base year, with 60% of its suppliers having science-based targets by 2025.